Immunome Reports Second Quarter 2023 Financial Results Exton, PA

Immunome Reports Second Quarter 2023 Financial

- August 9, 2023 - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical

company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient

care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

combining Immunome and Morphimmune's technologies represents a major step in our long-term

strategy of creating a preeminent oncology therapeutics company," stated Purnanand Sarma, PhD, President

and CEO of Immunome. "Targeted cancer therapies have made great strides in recent years, and the possible synergy

between Morphimmune's Targeted Effector Platform and Immunome's proprietary Discovery

Engine presents an opportunity to discover and develop truly novel therapies that can help cancer patients. We look forward to completing

the merger by the end the year."

Immunome is a biopharmaceutical company that utilizes its proprietary

human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company's focus is on discovering

and developing therapeutics in oncology internally and in collaboration with its partners.

Immunome's proprietary Discovery Engine identifies novel therapeutic

antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system,

isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity

antibodies that bind to cancer antigens or pathogens. Immunome's Discovery Engine incorporates high-throughput screening to enable

efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel

targets. The functional data Immunome generates differentiates Immunome's approach from those that use deep sequencing of B cells

to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility.

For more information, visit www.immunome.com.

Forward-Looking Statements

Cautionary Statement Regarding Forward-Looking

Certain statements contained in this communication

regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities

and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). These include,

but are not limited to, statements regarding the anticipated completion and effects of the proposed merger and private placement and related

timing; the combined company's planned clinical programs, including the timeline for filing of INDs and planned clinical trials;

the potential of the combined company's product candidates; the expected trading of the combined company's stock on Nasdaq;

management of the combined company; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts

for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunome

undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise,

except to the extent required by law. We use words such as "anticipates," "believes," "plans," "expects,"

"projects," "future," "intends," "may," "will," "should," "could,"

"estimates," "predicts," "potential," "continue," "guidance," and similar

expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such

forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ

materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the outcome of

any legal proceedings that may be instituted against Morphimmune or Immunome following the announcement of the merger; the inability to

complete the merger, including due to the inability to concurrently close the merger and the private placement of common stock or due

to failure to obtain approval of the stockholders of Immunome; delays in obtaining, adverse conditions contained in, or the inability

to obtain necessary regulatory approvals or complete regular reviews required to complete the merger, if any; the inability to recognize

the anticipated benefits of the merger, which may be affected by, among other things, competition, the ability of the combined company

to grow and successfully execute on its business plan; costs related to the merger; changes in the applicable laws or regulations; the

timing for achievement of milestones and the corresponding receipt of milestone payments; the possibility that the combined company may

be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for the combined company's

programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the

post-combination combined company or the expected benefits of the merger; the combined company's ability to manage future growth;

the combined company's ability to manage clinical trials or studies; the risk that pre-clinical data may not be predictive of clinical

data; the complexity of numerous regulatory and legal requirements that the combined company needs to comply with to operate its business;

the reliance on the combined company's management; the prior experience and successes of the combined company's management

team are not indicative of any future success; the dependence on the success of Morphimmune's targeted effector platform and Immunome's

human memory B cell platform; the failure to obtain, adequately protect, maintain or enforce the combined company's intellectual

property rights; and other risks and uncertainties indicated from time to time described in Immunome's Annual Report on Form 10-K

for the year ended December 31, 2022, the Registration Statement, once available, relating to the merger, including those under "Risk

Factors" therein, and in Immunome's other filings with the SEC. Immunome cautions that the foregoing list of factors is not

exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Morphimmune

and Immunome operate in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by

law, Immunome undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this press

release to conform these statements to actual results or to changes in their expectations.

Changes and Additional Information About the

Proposed Merger and Where to Find It

This communication is not intended to be, and

is not, a substitute for the proxy statement or any other document that Immunome has filed or may file with the Securities and Exchange

Commission ("SEC") in connection with the proposed merger.

In connection with the proposed merger, Immunome

has filed a registration statement on Form S-4 (File No. 333-273792) (the "Registration

Statement") with the SEC that includes a proxy statement/prospectus of Immunome, that will be both the proxy statement to be distributed

to holders of Immunome's common stock in connection with its solicitation of proxies for the vote by Immunome's stockholders

with respect to the proposed merger and other matters as may be described in the Registration Statement, as well as the prospectus relating

to the offer and sale of the securities to be issued in the proposed merger. The Registration Statement, including the proxy statement/prospectus

contained therein, contains important information about the proposed merger and the other matters to be voted upon at a meeting of Immunome's

stockholders to be held to approve the proposed merger and other matters (the "Merger Special Meeting"). Immunome may also

file other documents with the SEC regarding the proposed merger. Immunome stockholders and other interested persons are advised to read

the Registration Statement, including the proxy statement/prospectus contained therein, as well as any amendments or supplements thereto,

because they contain important information about the proposed merger. When available, the definitive proxy statement/prospectus will be

mailed to Immunome stockholders as of a record date to be established for voting on the proposed merger and the other matters to be voted

upon at the Merger Special Meeting.

No Offer or Solicitation

This press release is not a proxy statement or

solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall

neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in

any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities

laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10

of the Securities Act of 1933, as amended, or an exemption therefrom.

Participants in the Solicitation

Immunome, Morphimmune, and their respective directors,

executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from

Immunome's stockholders with respect to the proposed merger. Information regarding the persons who may be deemed participants

in the solicitation of proxies from Immunome's stockholders in connection with the proposed merger are contained in the proxy statement/prospectus

forming a part of the Registration Statement and will be contained in the definitive proxy statement/prospectus relating to the proposed

merger, when available, which will be filed with the SEC.

Condensed Balance Sheets

thousands, except share data)

The accompanying notes are an integral part of these unaudited condensed

financial statements.

Condensed Statements

except share and per share data)